Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. - Test2 - elhamkhani - TriplyDB

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.

http://www.wikidata.org/entity/Q36882123

about

Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.An analysis of trends and growth factor receptor expression of GI carcinoid tumors Pancreastatin predicts survival in neuroendocrine tumors.The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.Blood transcript analysis and metastatic recurrent small bowel carcinoid management.Microencapsulation of small intestinal neuroendocrine neoplasm cells for tumor model studies Gastric neuroendocrine tumours.Multidisciplinary reference centers: the care of neuroendocrine tumors.Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China.Multimodal management of neuroendocrine liver metastases.Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006.Identification of candidate serum proteins for classifying well-differentiated small intestinal neuroendocrine tumors Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy.Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms.Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinica Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution.Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence.Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution.The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.Gastric carcinoids: between underestimation and overtreatment.Consensus on biomarkers for neuroendocrine tumour disease Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.Disadvantage of survival outcomes in widowed patients with colorectal neuroendocrine neoplasm: an analysis of surveillance, epidemiology and end results database The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers.Atypical metastatic carcinoid of the uterine cervix and review of the literature.The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer.Neuroendocrine neoplasms of the gut and pancreas: new insights.

P2860

Q21089988-47A1C051-1CE3-424F-9AD4-D0C8103775F3 Q30884528-15389AC3-4242-44BC-B1EE-79C5AB010615 Q31170918-B1EA63AE-1C91-4185-9C15-CB826A162FFF Q33601383-FA906829-2204-466D-AD72-73D266F4DAC3 Q33737587-E8973579-A931-44C8-BCB7-43AE43DA0736 Q33985773-B7E9B461-C74C-4434-AAF3-5C00D4DD2171 Q34016884-03AEE48B-ED88-415F-8C09-B8B4B7F7B811 Q34031906-1E159FF5-0A87-4C17-82DE-F5135DA60068 Q34107681-09E2C34A-6B2B-449C-8E01-28CB754E8327 Q34204609-A1952B5F-1751-442C-A473-8C93C09B136E Q34306680-7D3AE9A7-911D-47B2-9ADB-DA1DD002E21E Q34335130-0C953CC6-A8D0-4439-AE38-5EB5ADC6750D Q34495609-3150F31D-0A6C-4FC5-AE2B-748FD67A1A13 Q34528199-BCC4BB24-D4B8-4429-B9E2-1DC36A3D8163 Q34610406-CA13D6D9-2B48-43AC-B75B-4F3A26B4CBF9 Q35055381-51941794-3E91-4404-9518-04583B153F70 Q35545959-26109D03-EBAA-4C33-8CAD-DE908C9CDA2C Q35550241-8AB777EA-D1AC-41F7-B1D4-F07177531DB2 Q35640506-40B0A804-7920-44F0-A8DB-2595DC5769EE Q35909807-50D426D7-ACCC-4438-8039-0BFAC8E7854E Q36009085-6C7E3612-4844-4E9E-8C2C-C0F5722B4C47 Q36359089-5D2464B9-D11E-4020-8E7C-83FCFCF03874 Q36790050-D3E85B8B-D8CD-4AF5-A4A4-E26E1AE99CAD Q36831573-99DF463A-8824-412D-8374-D231E47A1215 Q36871673-DA8DF4AF-BAE1-4256-ADE4-AA088D1FB60C Q36943954-E9281B1D-5748-4F23-80BA-13FF3D3A893B Q37085554-DF1358B5-0D64-46E1-A9BD-4939B833AB20 Q37116888-8527FB33-2644-4E99-853A-E8C565D269F4 Q37117596-2115CA6A-1255-4AED-9AD5-3947FB623423 Q37192619-FCF4B5F9-53A4-474A-9C60-0428342E6AC3 Q37255681-B71E6195-BD00-42D8-9936-46D81486A1BF Q37468838-AF55D4A2-3482-4116-BAAA-4FBD863E9229 Q37624511-B003B549-9617-4A0E-A4ED-B65B05A1A4E7 Q37634917-DAC678BD-8EC4-438A-8FE2-23C4F3AEED8C Q37696289-E4C5BCEE-5D9F-419D-A625-61C9B1890399 Q37846130-296C5E26-DAEE-4AB4-BDD0-7026FC562220 Q37849836-56A3BD1F-8212-4269-ABED-D4ACE180F76F Q37869391-E0A0D5D7-6FBD-4340-992B-C16DC6E8673E Q37875054-58F78AC4-6878-4AB7-9017-1A984EE83C42 Q37909911-81DD10A2-DE17-4905-8735-4A3E53B3C5F6

P2860

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.

http://www.wikidata.org/entity/Q36882123

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.

@en

type

label

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.

@en

prefLabel

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.

@en

P1433

Q36882123-6AAE7C91-6B2E-4AA6-B073-05C9BB39B815

P1476

Q36882123-941F0DAD-DB10-4AFD-82E4-AF007E39C943

P2093

Q36882123-2BDECD86-A42E-4C71-9EFC-AF128674D781

Q36882123-33496706-5575-40D9-BA50-A1BF288DE9C5

Q36882123-AF8AA143-8A97-4FAA-95C5-8FBBD2842D9C

Q36882123-B418A064-6F08-4EC1-A765-2B3F07A9C3CB

Q36882123-FCC4956E-6818-4F5F-B3A5-40504B6356D2

P2860

Q36882123-0AD711DB-2486-496B-814B-7EE15A3A194E

Q36882123-0C2090A4-09F6-42CE-9BEC-3AD2668FCE42

Q36882123-0F047CCD-BB19-4D07-9738-C730BC0FA72A

Q36882123-1A1FB7EB-1831-419F-A4F4-2998F84C6D93

Q36882123-1D92A6F2-CAAA-4A3C-9210-AE1E81B081CD

Q36882123-2028E0C9-C6C9-4E88-BE2C-20EF2E41F290

Q36882123-355AE3BB-524C-4D1C-AB2A-B8516D52E044

Q36882123-389B78EE-9129-4876-8614-B57AF7B04E9B

Q36882123-397208D6-E59D-428A-A7FF-2E2481E049B2

Q36882123-3D731C09-68E3-4630-9877-B665D730A9CA

P304

Q36882123-581D2608-C8E7-4E77-B537-6F34F9D291D8

P31

Q36882123-F72261DB-6EDF-4455-8C3F-93F557FA4DF2

P356

Q36882123-54D9A06C-1697-401E-9AD5-20E8C13160BC

P407

Q36882123-A2E3F71A-5DBF-4563-AAE5-401FA27677EE

P433

Q36882123-794F402F-7E22-43AF-A557-7AC44DEBBDD6

P478

Q36882123-A5539BB8-99EC-410D-9F16-F755ECC169DE

P577

Q36882123-039865D8-3BCA-43D0-8F6D-70818CD89457

P5875

Q36882123-F5A27D12-F8FE-44AD-8BF1-AFC172279BFB

P698

Q36882123-725D82A4-416B-4EB8-BD9C-EE1E444D5703

P932

Q36882123-4DD6393D-77FC-47D3-AF61-BD23753D44EE

P356

P1433

Journal of the National Cancer Institute

P1476

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.

@en

P2093

Daniel C Chung

http://www.w3.org/2001/XMLSchema#string

Elizabeth Snyderwine

http://www.w3.org/2001/XMLSchema#string

Irvin M Modlin

http://www.w3.org/2001/XMLSchema#string

Robert T Jensen

http://www.w3.org/2001/XMLSchema#string

Steven F Moss

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of stem cells in small intestine and colon by marker gene Lgr5

Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia

The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept

Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment

Gastroenteropancreatic neuroendocrine tumours

Drugs and valvular heart disease

Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice

Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues

A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors

Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity.

P304

1282-1289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJN275

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23246643

http://www.w3.org/2001/XMLSchema#string

P698

18780869

http://www.w3.org/2001/XMLSchema#string

P932

2538549

http://www.w3.org/2001/XMLSchema#string